Memantine RCT
- Conditions
- Malignant glioma classified as Grade3-4 by WHO classification 2016gliobalastoma, anaplastic astrocytoma,anaplastic oligodendroglioma9440,9441,9442/3,9401,9451,9460,9382
- Registration Number
- JPRN-jRCTs071190010
- Lead Sponsor
- Ishiuchi Shogo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 29
Patients with malignant glioma who are classified as Grade3 to 4 of WHO classification 2016 using neuroradiological and histopathological diagnostic methods and undergo hyperbaric oxygen therapy and irradiation therapy.
1. Patients with hypersensitivity to the study drug.
2. Patients with impaired renal function.
3. Patients with factors that raise urine pH (tubular acidosis, severe urinary tract infection etc.).
4. Patients with advanced liver function disorder.(1. Increase in T-Bil, AST, ALT, ALP, gamma-GTP of CTACAE v4.0 grade2 or more, 2. Accompanied by abnormality of coagulation factor, 3. Suspected diseases of hepatobiliary system etc.).
5. Pregnant women, lactating women or ladies who may be pregnant.
6. Patients who require continued administration of drugs that may interact with the study drug (Dopamine agonist, hydrochlorothiazide, drug excreted by renal tubule secretion, drug causing urinary alkalization, drug having NMDA receptor antagonism).
7. Patients judged inappropriate as subjects of this study by research doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hippocampal function including recognition test<br>Higher brain function including excusive function
- Secondary Outcome Measures
Name Time Method Overall survival, Progression free survival<br>Hippocampal neurogenesis, Microstructure of white matter fiber, Quality of Life